Oncotarget

Research Papers:

Zingerone suppresses angiogenesis via inhibition of matrix metalloproteinases during tumor development

Woom-Yee Bae, Jae-Sun Choi, Ja-Eun Kim, Chan Park and Joo-Won Jeong _

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:47232-47241. https://doi.org/10.18632/oncotarget.10030

Metrics: PDF 1807 views  |   HTML 1947 views  |   ?  


Abstract

Woom-Yee Bae1,*, Jae-Sun Choi1,*, Ja-Eun Kim2,3, Chan Park1,2, Joo-Won Jeong1,2

1Department of Biomedical Science, Graduate School, Kyung Hee University, Seoul, 02447, Republic of Korea

2Department of Anatomy and Neurobiology, School of Medicine, Kyung Hee University, Seoul, 02447, Republic of Korea

3Department of Pharmacology, School of Medicine, Kyung Hee University, Seoul, 02447, Republic of Korea

*These authors contributed equally to this work

Correspondence to:

Joo-Won Jeong, email: [email protected]

Keywords: zingerone, angiogenesis, cancer, matrix metalloproteinases, JNK

Received: April 25, 2016     Accepted: June 04, 2016     Published: June 14, 2016

ABSTRACT

Angiogenesis is an essential step for tumor survival and progression, and the inhibition of angiogenesis is a good strategy for tumor therapeutics. In this study, we investigated the therapeutic effect of zingerone in a mouse tumor model. Zingerone suppressed tumor progression and tumor angiogenesis. Moreover, we found that zingerone inhibited the angiogenic activities of endothelial cells by both direct and indirect means. A mechanistic study showed that the activities of MMP-2 and MMP-9 in tumor cells were decreased by treatment with zingerone. Interestingly, zingerone-mediated inhibition of MMP-2 and MMP-9 was involved in the JNK pathway. In conclusion, zingerone showed strong anti-angiogenic activity via the inhibition of MMP-2 and MMP-9 during tumor progression, suggesting that zingerone may be a potential therapeutic drug for human cancers.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 10030